Marek Ciszewski on Clubhouse

Bio

Attorney and life long biotech investor. Formerly global head of equity research at BMO Global
Asset Mgmt. In charge of HC sleeve (~$8 bil). Moved into the industry in various sr. roles in Finance and BD&L. Several lead drug failures later, figured there was a better way to develop drugs. Thus, started a VC fund to focus on AI/ML approaches. Ultimately yielding a portfolio of six companies. Joined Lantern Pharma (LTRN), IPO in June 2020. And now, Landos Biopharma (LABP). IPO in Feb. 2021. Both use proprietary AI platforms. LABP focused on the discovery and development of novel auto-immune pathways and drugs. Now 17 programs in active development. Lead drug, omilancor in goobal registration directed P3 program in UC. P2 data reported in early 2021 shows omilancor to be a best in class therapeutic. Oral. Gut restricted. One word to describe me: Curious! I love networking and learning about new business models, particularly those leading to creative destruction.